PRA GROUP INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PRA GROUP INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.11B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $802.55M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $966.52M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.10B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.07B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.02B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $908.26M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $828.21M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $930.60M | Mar 12, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $14.70M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $9.75M | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $15.77M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $14.92M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $24.92M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $77.38M | Mar 12, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($305.14M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $70.60M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($83.48M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $117.15M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $183.16M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $149.34M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $86.16M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $65.56M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $164.32M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $86.26M | Mar 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.27M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $339.73M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $100.49M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $285.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $375.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $349.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $247.69M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $185.26M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $213.73M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $219.75M | Mar 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $1.30M | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $1.30M | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $1.30M | Feb 28, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($85.54M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($94.59M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($97.54M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $21.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $84.93M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $141.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $133.39M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $80.87M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $15.48M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $205.90M | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.82M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.05M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $2.89M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $13.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $11.21M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $17.23M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $18.03M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $20.52M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $22.84M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $14.16M | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.10B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.93B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $4.53B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.18B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.37B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.45B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.42B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.91B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $3.70B | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $3.16B | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.06B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.74B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $3.29B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.89B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.04B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.08B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $3.20B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.78B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $2.55B | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $2.24B | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $979.85M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.17B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.23B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.29B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.34B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.17B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.10B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.09B | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $864.30M | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $396.36M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $431.56M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $435.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $480.26M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $492.99M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $480.79M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $464.12M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $526.51M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $499.91M | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.56B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.49B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.57B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.55B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.51B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.36B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.28B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.21B | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.05B | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.41M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $105.94M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $112.53M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $83.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $87.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $108.61M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $119.77M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $98.70M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $120.52M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $94.29M | Mar 12, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $1.82B | Mar 1, 2017 |
| FY2012 | Dec 31, 2012 | $200.54M | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $1.25M | Feb 28, 2013 |
| FY2011 | Dec 31, 2010 | $2.40M | Feb 28, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 3 | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Mar 12, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 3 | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Mar 12, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.45M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 39.51M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 39.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 38.98M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 41.01M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 45.59M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 45.42M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 45.30M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 45.19M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 46.36M | Feb 28, 2018 |